F. Iuliano

443 total citations
9 papers, 328 citations indexed

About

F. Iuliano is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, F. Iuliano has authored 9 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 6 papers in Genetics and 3 papers in Oncology. Recurrent topics in F. Iuliano's work include Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). F. Iuliano is often cited by papers focused on Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). F. Iuliano collaborates with scholars based in Italy and Lebanon. F. Iuliano's co-authors include Marilina Amabile, Elisabetta Abruzzese, Antonio Tabilio, Donatella Raspadori, Francesco Forconi, Monica Bocchia, Francesco Lauria, Sergio Amadori, S Gentili and Alessandro Gozzetti and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

F. Iuliano

9 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Iuliano Italy 6 256 204 145 86 68 9 328
F.-X. Mahon France 11 323 1.3× 268 1.3× 162 1.1× 51 0.6× 34 0.5× 20 414
Peter Rohoň Czechia 9 208 0.8× 155 0.8× 71 0.5× 66 0.8× 67 1.0× 33 283
Alfonso Quintás-Cardama United States 9 305 1.2× 265 1.3× 185 1.3× 58 0.7× 28 0.4× 17 416
Francesco Iuliano Italy 6 112 0.4× 100 0.5× 52 0.4× 46 0.5× 61 0.9× 17 182
Arta Dreimane Sweden 9 296 1.2× 246 1.2× 123 0.8× 74 0.9× 19 0.3× 17 347
Takashi Kumagai Japan 10 266 1.0× 224 1.1× 134 0.9× 54 0.6× 52 0.8× 28 306
Edward Kavalerchik United States 6 244 1.0× 142 0.7× 58 0.4× 125 1.5× 25 0.4× 17 358
Jimmie H. Harvey United States 6 115 0.4× 144 0.7× 51 0.4× 49 0.6× 29 0.4× 9 285
Alicia Senín Spain 9 284 1.1× 282 1.4× 97 0.7× 81 0.9× 18 0.3× 21 405
Mary Alikian United Kingdom 11 204 0.8× 177 0.9× 55 0.4× 80 0.9× 22 0.3× 18 346

Countries citing papers authored by F. Iuliano

Since Specialization
Citations

This map shows the geographic impact of F. Iuliano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Iuliano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Iuliano more than expected).

Fields of papers citing papers by F. Iuliano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Iuliano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Iuliano. The network helps show where F. Iuliano may publish in the future.

Co-authorship network of co-authors of F. Iuliano

This figure shows the co-authorship network connecting the top 25 collaborators of F. Iuliano. A scholar is included among the top collaborators of F. Iuliano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Iuliano. F. Iuliano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Castagnetti, Fausto, Francesca Palandri, Marilina Amabile, et al.. (2009). Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 113(15). 3428–3434. 53 indexed citations
2.
Palandri, Francesca, Ilaria Iacobucci, Fausto Castagnetti, et al.. (2008). Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome. Haematologica. 93(5). 770–774. 38 indexed citations
3.
Rosti, G., Ilaria Iacobucci, Fausto Castagnetti, et al.. (2007). Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 92(1). 101–105. 39 indexed citations
4.
Iuliano, F., et al.. (2006). Clinical and hematological improvement in patients receiving liposome doxorubicin (Myocet) therapy for myelofibrosis with myeloid metaplasia (MMM). Journal of Clinical Oncology. 24(18_suppl). 6593–6593. 1 indexed citations
5.
Bocchia, Monica, S Gentili, Elisabetta Abruzzese, et al.. (2005). Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. The Lancet. 365(9460). 657–662. 183 indexed citations
6.
Molica, Stefano, et al.. (2004). Prevalence of inherited and acquired risk factors for venous thromboembolic (VTE) disease among women with breast cancer taking adjuvant tamoxifen (TAM). Journal of Clinical Oncology. 22(14_suppl). 802–802. 5 indexed citations
7.
Battaglia, C, et al.. (2004). Prevalence of inherited and acquired risk factors for venous thromboembolic (VTE) disease among women with breast cancer taking adjuvant tamoxifen (TAM). Journal of Clinical Oncology. 22(14_suppl). 802–802. 2 indexed citations
8.
9.
Bocchia, Monica, S Gentili, Elisabetta Abruzzese, et al.. (2003). A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon. Use Siena air (University of Siena). 89. 123–123. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F.-X. Mahon Breakdown of academic impact, for papers by Peter Rohoň Breakdown of academic impact, for papers by Alfonso Quintás-Cardama Breakdown of academic impact, for papers by Francesco Iuliano Breakdown of academic impact, for papers by Arta Dreimane Breakdown of academic impact, for papers by Takashi Kumagai Breakdown of academic impact, for papers by Edward Kavalerchik Breakdown of academic impact, for papers by Jimmie H. Harvey Breakdown of academic impact, for papers by Alicia Senín Breakdown of academic impact, for papers by Mary Alikian
Rankless by CCL
2026